News

The US District Court for the Southern District of Indiana has upheld Eli Lilly and company’s method-of-use patents on Evista (raloxifene HCl tablets). In the case of Eli

Frutarom has announced a new satiety and obesity study using its FenuLife galactomannan ingredient and has revealed positive results. The company said that the study revealed an increase

Genzyme is now approximately half-way through the anticipated shortage period for Cerezyme and Fabrazyme. The restart of the Allston landing manufacturing facility is complete, and if production continues

Edwards Lifesciences has announced that the Court of Appeals for the Federal Circuit affirmed a previous court decision in favor of Cook and WL Gore & Associates. The

Keryx Biopharmaceuticals has announced results of the Open Label Extension (OLE) trial of Zerenex for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage

Gilead Sciences has revealed that the European Commission has granted conditional marketing authorisation for Cayston 75mg powder and solvent for nebuliser solution for the suppressive therapy of chronic

GATC Biotech has revealed that it is now offering human genome sequencing services using enrichment technologies from Agilent along with sequencing systems such as Roche GS FLX and

Bayer HealthCare and Onyx Pharmaceuticals have announced the full results from the randomised, double-blind, placebo controlled phase II trial showing that Nexavar (sorafenib tablets) in combination with the

Pharming Group has received confirmation of validation from EMEA of its Marketing Authorization Application (MAA) for Rhucin. Consequently the formal scientific evaluation procedure of the European Medicines Agency